Advertisement
Home » Deep Dives » CONDITION SPOTLIGHT » Condition Spotlight: Tardive Dyskinesia » VMAT2 Inhibitors May Improve Well-Being in Addition to TD Symptoms

Condition Spotlight: Tardive Dyskinesia

VMAT2 Inhibitors May Improve Well-Being in Addition to TD Symptoms

Oct 17, 2023

REFERENCES & ADDITIONAL READING

Exploring Real-World Symptom Impact and Improvement in Well-Being Domains for Tardive Dyskinesia in VMAT2 Inhibitor-Treated Patients Via Clinician Survey and Chart Review
https://meridian.allenpress.com/mhc/article/13/5/225/496174/Exploring-real-world-symptom-impact-and

ABOUT THE EXPERTS

  • Jonathan M. Meyer, MD

    Assistant Clinical Professor of Psychiatry
    University of California San Diego

    Jonathan M. Meyer, MD, has indicated to Physician’s Weekly that he has received consulting fees from Acadia Pharmaceuticals, Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine Biosciences, Otsuka America, Sunovion Pharmaceuticals, and Teva Pharmaceuticals and honoraria from Alkermes Intra-Cellular, Neurocrine Biosciences, Noven, Sunovion, and Teva for lectures, presentations, speaker bureaus, manuscript writing, or educational events.

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement